Brits Lead Charge In Global Battle Against Antimicrobial Resistant Superbugs

During the annual BIO International conference in June, researchers from the UK – which has pushed antimicrobial resistance to front and center on the global stage – discussed ongoing efforts for incentivizing antibiotic discovery and development, and the challenges that remain when it comes to management and resolution of the world’s AMR crisis.

Tackling an unmet need is a common focus for pharmaceutical companies when choosing the therapeutic areas they will concentrate on – but it is often not enough. Pharma business executives have also got to be able to see a clear route to returns on their investments. While no one doubts the huge medical challenge antimicrobial resistance (AMR) poses, how to incentivize companies to work on solutions is proving to be more difficult. During BIO 2018, held in Boston, June 4-7, researchers from the UK discussed what efforts were being made to devise incentivization models.

The numbers verge on the apocalyptic. Currently, more than 50,000 people a year in the EU and US die from...

More from Innovation

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.